Arbutus Biopharma (ABUS) Files $250M Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M
November 4, 2021 7:45 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $3.34 million versus the consensus estimate of $2.38 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
... More